●
Earnings Feed
Filings
Companies
Insiders
Pricing
Blog
⌘
K
Login
Start Free
GENAISSANCE PHARMACEUTICALS INC
·
10-Q
Aug 9, 9:07 AM ET
Share
GENAISSANCE PHARMACEUTICALS INC 10-Q
Loading document...
Share
More
Contents
13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 10-Q
For The Quarterly Period Ended June 30, 2005
Delaware
06-1338846
Notes to Unaudited Condensed Consolidated Financial Statements
Overview
Critical Accounting Policies and Estimates
Risks to Genaissance if the Proposed Merger Transaction Is Not Completed
If the merger is not completed, our stock price and future business and operations could be adversely affected.
Our market price may be negatively impacted if the merger with Clinical Data is not concluded.
The termination fee and the restrictions on solicitation contained in the merger agreement and the terms of the voting agreements may discourage other companies from trying to acquire us.
Contents
Share
More
Download PDF